Adult immunization against hepatitis B: Does the number of jabs matter?

被引:1
作者
Oster, Gerry [1 ]
Bornheimer, Rebecca [1 ]
Ottino, Kevin [1 ]
Stevenson, Catherine [2 ]
Lewin, Clem [3 ]
Janssen, Robert [2 ]
机构
[1] Policy Anal Inc PAI, 822 Boylston St,Suite 206, Chestnut Hill, MA 02467 USA
[2] Dynavax Technol Corp, Emeryville, CA USA
[3] CSL Vaccine Consulting, Orange, CT USA
关键词
Hepatitis B; Adults; Vaccination; Adherence; Seroprotection; Three-dose vs two-dose; COST-EFFECTIVENESS; VACCINE; SAFETY; IMMUNOGENICITY;
D O I
10.1016/j.vaccine.2022.04.080
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: At least one-half of adults beginning an immunization series with a three-dose hepatitis B virus (HBV) vaccine (ENGERIX-B, RECOMBIVAX-B) have been reported not to receive the third dose. Use of a two-dose vaccine may improve adherence and lead to greater overall levels of seroprotection. Objective: To examine expected levels of adherence and overall seroprotection at one year among adults in routine clinical settings beginning an immunization series with either ENGERIX-B or the two-dose HBV vaccine, HEPLISAV-B. Methods: Decision-analytic model comparing expected levels of adherence and overall seroprotection at one year among a hypothetical cohort of one million previously unvaccinated adults aged >= 30 years receiving first doses of either ENGERIX-B or HEPLISAV-B in a routine clinical setting. We stratified the population by age (30-49 years vs >= 50 years) to allow for possible differences in adherence and seroprotection. We estimated our model using published adherence rates for HBV vaccines, and reported seroprotection rates by number of doses administered. We also compared total expected costs of HBV immunization with each vaccine. Results: Use of a two-dose rather than three-dose HBV vaccine would increase the expected number of adults seroprotected at one year by 275,000 per one million persons beginning immunization series, largely reflecting a gain of 290,000 in the expected number of persons fully vaccinated. Results were similar for the two age groups. While the cost per dose of HEPLISAV-B exceeds that of ENGERIX-B, its estimated mean cost per person seroprotected at one year is $50-$70 (similar to 15%) lower. Conclusions: Use of a two-dose HBV vaccine would increase the number of adults fully seroprotected at one year compared with the number expected with a three-dose vaccine. Notwithstanding its higher unit cost, mean expected cost per person seroprotected is substantially lower for HEPLISAV-B than ENGERIX-B as a result of much higher levels of seroprotection. (C) 2022 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:3597 / 3604
页数:8
相关论文
共 50 条
  • [21] Efficacy of immunization against hepatitis B virus infection in acute leukemia
    Dolai, Tuphan Kanti
    Mahapatra, Manoranjan
    Pati, Hara Prasad
    Mishra, Pravas
    Seth, Tulika
    Bhargava, Rahul
    Rathi, Shyam
    Rathod, Niranjan
    Saxena, Renu
    TURKISH JOURNAL OF HEMATOLOGY, 2010, 27 (03) : 156 - 161
  • [22] STRATEGIES FOR IMMUNIZATION AGAINST HEPATITIS-B IN WESTERN-EUROPE
    IWARSON, S
    VACCINE, 1993, 11 : S18 - S20
  • [23] DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus
    Davis, HL
    MOUNT SINAI JOURNAL OF MEDICINE, 1999, 66 (02): : 84 - 90
  • [24] Efficacy of immunization against hepatitis B virus infection in children with cancer
    Meral, A
    Sevinir, B
    Günay, Ü
    MEDICAL AND PEDIATRIC ONCOLOGY, 2000, 35 (01): : 47 - 51
  • [25] Effectiveness Analysis of the Immunization Against Hepatitis B in Liver Transplantation Patients
    Rodrigues, Isabela Cristina
    da Silva, Renato Ferreira
    Martins Alves da Silva, Rita de Cassia
    Camarero de Felicio, Helen Catharine
    TRANSPLANTATION PROCEEDINGS, 2020, 52 (05) : 1365 - 1369
  • [26] Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination
    Janssen, Robert S.
    Bruxvoort, Katia
    Jacobsen, Steven J.
    Slezak, Jeff
    David, Coline
    Hyer, Randall
    Poland, Gregory A.
    VACCINE, 2021, 39 (39) : 5666 - 5672
  • [27] Why does gender matter for immunization?
    Tracey, Goodman
    Olivia, Bullock
    Jean, Munro
    Megan, Holloway
    Sagri, Singh
    VACCINE, 2024, 42 : S91 - S97
  • [28] The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy
    Chen, Shiyi
    Zhao, Yuping
    Yang, Zhiyao
    Li, Ying
    Shi, Hongyuan
    Zhao, Ting
    Yang, Xiaolei
    Li, Jing
    Li, Guoliang
    Wang, Jianfeng
    Ying, Zhifang
    Yang, Jingsi
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (01)
  • [29] Efficacy and safety of vaccination against hepatitis A and B in patients with chronic liver disease
    de Artaza Varasa, Tomas
    Sanchez Ruano, Juan Jose
    Garcia Vela, Almudena
    Gomez Rodriguez, Rafael
    Romero Gutierrez, Marta
    de la Cruz Perez, Gema
    Gomez Moreno, Ana Zaida
    Carrobles Jimenez, Jose Maria
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2009, 32 (07): : 483 - 488
  • [30] An economic analysis of adult hepatitis B vaccination in China
    Zheng, Hui
    Wang, Fu-zhen
    Zhang, Guo-min
    Cui, Fu-qiang
    Wu, Zhen-hua
    Miao, Ning
    Sun, Xiao-jin
    Liang, Xiao-feng
    Li, Li
    VACCINE, 2015, 33 (48) : 6831 - 6839